A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the bioequivalence of 500 mg Azithromycin FC tablets
(Azivol) produced by PT. Novell Pharmaceutical Laboratories, compared to the reference
product Zithromax 500 mg FC tablet produced by Pfizer Australia Pty, Ltd